Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €17.75 EUR
Change Today +0.03 / 0.17%
Volume 21.6K
NANO On Other Exchanges
EN Paris
As of 11:35 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

nanobiotix (NANO) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/22/14 - €25.00
52 Week Low
12/16/14 - €14.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NANOBIOTIX (NANO)

Related News

No related news articles were found.

nanobiotix (NANO) Related Businessweek News

No Related Businessweek News Found

nanobiotix (NANO) Details

Nanobiotix S.A., an oncology focused nanomedicine company, engages in the development of tools for the treatment of cancer in France and internationally. The company develops NanoXray, a pipeline of patented products that include NBTXR3 nanoparticles, which are designed for direct injection into the tumor; NBTX-IV nanoparticles designed for intravenous injection to reach the tumor and the surrounding tissue; and NBTX-TOPO nanoparticles that are formulated as a gel to be applied during surgery after removal of the tumor in various types of breast cancer, brain tumors, and retroperitoneal soft tissue sarcomas. It also develops nanoMag magnetic particles for the treatment and diagnostic of cancer; and nanoPDT laser activated nanoparticles for the treatment of cancer. The company has a business and development collaboration with Malaysian Biotech Corp. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

49 Employees
Last Reported Date: 05/1/15
Founded in 2003

nanobiotix (NANO) Top Compensated Officers

Co-Founder, President of The Executive Board ...
Total Annual Compensation: €268.8K
Chief Financial Officer and Member of the Exe...
Total Annual Compensation: €192.0K
Chief Medical Officer, Medical Director and M...
Total Annual Compensation: €217.0K
Head of Business Development and Member of Ex...
Total Annual Compensation: €185.6K
Compensation as of Fiscal Year 2014.

nanobiotix (NANO) Key Developments

Nanobiotix Announces Revenue Results for the Second Quarter and First Half of 2015

Nanobiotix announced revenue results for the second quarter and first half of 2015. For the quarter, revenues were $46,189 against $48,596 a year ago. For the first half, revenues were $93,180 against $93,939 a year ago.

Nanobiotix Starts Phase I/II Clinical Trial in Liver Metastasis and Hepatocellular Cancer with its Lead Product Nbtxr3

NANOBIOTIX has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. The French National Agency for Medicines and Health Products gave Nanobiotix the green light to start a Phase I/II trial in two new cancer populations - hepatocellular cancer (HCC) and liver metastases - for its lead product, NBTXR3. The multinational, non-randomized, open phase I/II study will evaluate the use of NBTXR3 with high precision radiation therapy, delivered as high dose fractions (SBRT - Stereotatic Body Radiation Therapy). This type of therapy is the safest and most modern radiotherapy currently available for the treatment of malignant liver tumors. Nanobiotix's liver cancer trial has been supported by a broad NBTXR3 preclinical program specific to these cancers showing that the use of the product is feasible and well tolerated in animals. Radiation therapy has been shown to improve clinical outcomes, including survival with clinical trials showing a direct correlation between higher doses of radiation therapy and better outcomes. However, high doses of radiation in the liver (vital organ) are not usually feasible. SBRT has been shown to be efficient only in specific subsets of population with small tumors. Complete response is a rare event and local control is often compromised in big tumors, metastases and HCC with portal vein tumor thrombosis and short progression Free Survival and Overall survival. NBTXR3 is activated by radiotherapy and works by the deposit of increased energy doses (radio-enhancement) within the tumor. NBTXR3 may significantly increase the intratumor energy dose with higher destruction an improve the patient outcome in terms of higher tumor shrinkage, local control and overall survival.

Nanobiotix SA Presents at French Life Science Days conference, Jun-17-2015

Nanobiotix SA Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NANO:FP €17.75 EUR +0.03

NANO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NANO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NANO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 80.5x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 69.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOBIOTIX, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at